Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bifonazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | IDO1 | P14902 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bifonazole SCHEMBL36803 | 1.00 | CYP17A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| Bifonazole SCHEMBL1606037 | 1.00 | CYP17A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| Bifonazole SCHEMBL7598897 | 1.00 | CYP17A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| Bifonazole SCHEMBL394764 | 1.00 | CYP17A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL11349905 | 0.98 | CYP17A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL25873391 | 0.92 | CYP17A1 (0.85) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL738495 | 0.91 | CYP19A1 (1.00) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL24177881 | 0.91 | CYP17A1 (0.82) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL11362753 | 0.91 | CYP17A1 (0.85) | CYP17A1MEN1NR1I2USP2ABCB11 | |
| SCHEMBL11353276 | 0.91 | CYP19A1 (0.91) | CYP17A1MEN1NR1I2USP2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0230226-B1 | ANTIMYCOTIC EMULSIONS | Kali-Chemie Pharma GmbH (DE) | 1991-08-07 | — | — | EP | claimed |
| EP-0055396-B1 | ANTIFUNGAL COMPOSITIONS WITH A HIGH RELEASE RATE OF THE DRUG AS AN ELASTIC LIQUID DRESSING | BAYER AG (DE) | 1985-01-23 | — | — | EP | claimed |
| EP-0054205-B1 | ANTI-FUNGAL COMPOSITION IN EMULSION FORM WITH A HIGHER RELEASE RATE OF THE DRUG | BAYER AG (DE) | 1985-01-16 | — | — | EP | claimed |
| EP-0055397-B1 | ANTIFUNGAL COMPOSITIONS WITH A HIGH RELEASE RATE OF THE DRUG AS AN ELASTIC LIQUID DRESSING | BAYER AG (DE) | 1984-08-22 | — | — | EP | claimed |
| US-4457938-A | AZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-07-03 | — | — | US | claimed |
| EP-0058887-B1 | ANTIFUNGAL COMPOSITIONS WITH A HIGHER RATE OF THE DRUG RELEASE AS A STICK | BAYER AG (DE) | 1984-04-11 | — | — | EP | claimed |
| EP-2180887-B1 | PHARMACEUTICAL PREPARATIONS CONTAINING HIGHLY VOLATILE SILICONES | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2022-12-28 | — | — | EP | disclosed |
| EP-2313039-B1 | KIT FOR THE TREATMENT OF ONYCHOMYCOSIS | FABRE PIERRE DERMO COSMETIQUE (FR) | 2022-08-31 | — | — | EP | disclosed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | disclosed |
| US-20220193037-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE AZOLATED LOCAL ANTIFUNGAL SUBSTANCE | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2022-06-23 | — | — | US | disclosed |
| CN-113243374-B | Heterocyclic compounds as pesticides | 拜耳农作物科学股份公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-113243374-A | Heterocyclic compounds as pesticides | 拜耳农作物科学股份公司 | 2021-08-13 | — | — | CN | disclosed |
| CN-108477173-B | Heterocyclic compounds as pesticides | 拜耳农作物科学股份公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20020197291-A1 | Composition for removing abnormal keratinous material | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002098380-A1 | PREPARATION FOR THE REMOVAL OF ABNORMAL KERATIN MATERIAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-12 | — | — | WO | disclosed |
| EP-0796841-B1 | Bis alkanoyl esters of carnitine having bactericidal, fungicidal and antiprotozoal activity | SIGMA TAU IND FARMACEUTI (IT) | 2000-05-31 | — | — | EP | disclosed |
| US-5925369-A | FOR TREATMENT OF SKIN INFECTIONS | SCAFETTA NAZARENO (IT) | 1999-07-20 | — | — | US | disclosed |
| EP-0923935-A1 | EXTERNAL PREPARATION FOR CURING LESIONED TISSUES | Chuyakuken, Ltd. (JP) | 1999-06-23 | — | — | EP | disclosed |
| WO-1996025162-A1 | MEANS FOR TREATING ONYCHOMYCOSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1996-08-22 | — | — | WO | disclosed |
| EP-0395476-A2 | Method and apparatus for the production of ionic cloths for use in ionic dressings | RICOH KYOSAN INC. (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | CYP17A1 338/4885MEN1 1533/4885NR1I2 2301/4885 |
| US-20220193037-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE AZOLATED LOCAL ANTIFUNGAL SUBSTANCE | ERG28, UGCG, DEGS1 | CYP17A1 44/4885MEN1 1558/4885NR1I2 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.